Proper storage and handling practices help preserve product integrity, stability, and overall quality
No pivotal trials have led to a New Drug Application submission for CJC-1295 post-2009
Although MOTS-C has gained attention in wellness and longevity spaces, it is not FDA-approved for improving metabolism, enhancing exercise performance, boosting energy, supporting weight management, or treating any medical condition
This is acceptable and won't significantly impair results, but daily dosing produces faster fat loss
Who should avoid IGF-1 LR3 Certain individuals should not use IGF-1 LR3 under any circumstances: Absolute Contraindications : Active cancer or history of hormone-sensitive tumors Severe diabetes or uncontrolled blood sugar Pregnancy or nursing mothers History of organ enlargement Active blood clotting disorders Relative Contraindications (may require specialty medical clearance): History of diabetes Cardiovascular conditions Autoimmune disorders Kidney or liver dysfunction History of growth disorders Before starting IGF-1 LR3, comprehensive health screening is essential
